Phaseline

Companies › Meribank Biotech

Meribank Biotech: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Other, Respiratory; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
UMC119-06-05
allogeneic umbilical cord mesenchymal stem cells
–Phase 2Chronic Obstructive Pulmonary Disease; Pathologic ProcessesDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06501066UMC119-06-05Phase 1Pathologic ProcessesOtherDec 2026
NCT06491043UMC119-06-05Phase 2Chronic Obstructive Pulmonary DiseaseRespiratoryDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Photozig MaaT Pharma Serum Life Science Europe Distribuidora Biolife SA de CV Circul'Egg

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.